Fibromyalgia (FM) is a medical condition characterised by chronic widespread pain and a heightened pain response to pressure.
The APAC is a major untapped market with many leading vendors in the global fibromyalgia drugs market.
Market Analysis and Insights: Global Fibromyalgia Drugs Market
The global Fibromyalgia Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Fibromyalgia Drugs Scope and Market Size
Fibromyalgia Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Fibromyalgia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
Pfizer
Eli Lilly
Actavis
Merck Sharp and Dohme
Daiichi Sankyo
Innovative Med Concepts
Meda
Meiji Seika
Switch Biotech
Theravance
Zynerba Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. (TNXP)
Fibromyalgia Drugs Breakdown Data by Type
Serotonin Norepinephrine Reuptake Inhibitors
GABA Analogs
Other
Fibromyalgia Drugs Breakdown Data by Application
Hospitals
Clinics
Other
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Fibromyalgia Drugs Revenue
1.4 Market by Type
1.4.1 Global Fibromyalgia Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Serotonin Norepinephrine Reuptake Inhibitors
1.4.3 GABA Analogs
1.4.4 Other
1.5 Market by Application
1.5.1 Global Fibromyalgia Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Fibromyalgia Drugs Market Perspective (2015-2026)
2.2 Global Fibromyalgia Drugs Growth Trends by Regions
2.2.1 Fibromyalgia Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Fibromyalgia Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Fibromyalgia Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Fibromyalgia Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Fibromyalgia Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Fibromyalgia Drugs Players by Market Size
3.1.1 Global Top Fibromyalgia Drugs Players by Revenue (2015-2020)
3.1.2 Global Fibromyalgia Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Fibromyalgia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Fibromyalgia Drugs Market Concentration Ratio
3.2.1 Global Fibromyalgia Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Fibromyalgia Drugs Revenue in 2019
3.3 Fibromyalgia Drugs Key Players Head office and Area Served
3.4 Key Players Fibromyalgia Drugs Product Solution and Service
3.5 Date of Enter into Fibromyalgia Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Fibromyalgia Drugs Historic Market Size by Type (2015-2020)
4.2 Global Fibromyalgia Drugs Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Fibromyalgia Drugs Market Size by Application (2015-2020)
5.2 Global Fibromyalgia Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Fibromyalgia Drugs Market Size (2015-2020)
6.2 Fibromyalgia Drugs Key Players in North America (2019-2020)
6.3 North America Fibromyalgia Drugs Market Size by Type (2015-2020)
6.4 North America Fibromyalgia Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Fibromyalgia Drugs Market Size (2015-2020)
7.2 Fibromyalgia Drugs Key Players in Europe (2019-2020)
7.3 Europe Fibromyalgia Drugs Market Size by Type (2015-2020)
7.4 Europe Fibromyalgia Drugs Market Size by Application (2015-2020)
8 China
8.1 China Fibromyalgia Drugs Market Size (2015-2020)
8.2 Fibromyalgia Drugs Key Players in China (2019-2020)
8.3 China Fibromyalgia Drugs Market Size by Type (2015-2020)
8.4 China Fibromyalgia Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Fibromyalgia Drugs Market Size (2015-2020)
9.2 Fibromyalgia Drugs Key Players in Japan (2019-2020)
9.3 Japan Fibromyalgia Drugs Market Size by Type (2015-2020)
9.4 Japan Fibromyalgia Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Fibromyalgia Drugs Market Size (2015-2020)
10.2 Fibromyalgia Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Fibromyalgia Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Fibromyalgia Drugs Market Size by Application (2015-2020)
11 India
11.1 India Fibromyalgia Drugs Market Size (2015-2020)
11.2 Fibromyalgia Drugs Key Players in India (2019-2020)
11.3 India Fibromyalgia Drugs Market Size by Type (2015-2020)
11.4 India Fibromyalgia Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Fibromyalgia Drugs Market Size (2015-2020)
12.2 Fibromyalgia Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Fibromyalgia Drugs Market Size by Type (2015-2020)
12.4 Central & South America Fibromyalgia Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Fibromyalgia Drugs Introduction
13.1.4 Pfizer Revenue in Fibromyalgia Drugs Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Eli Lilly
13.2.1 Eli Lilly Company Details
13.2.2 Eli Lilly Business Overview
13.2.3 Eli Lilly Fibromyalgia Drugs Introduction
13.2.4 Eli Lilly Revenue in Fibromyalgia Drugs Business (2015-2020)
13.2.5 Eli Lilly Recent Development
13.3 Actavis
13.3.1 Actavis Company Details
13.3.2 Actavis Business Overview
13.3.3 Actavis Fibromyalgia Drugs Introduction
13.3.4 Actavis Revenue in Fibromyalgia Drugs Business (2015-2020)
13.3.5 Actavis Recent Development
13.4 Merck Sharp and Dohme
13.4.1 Merck Sharp and Dohme Company Details
13.4.2 Merck Sharp and Dohme Business Overview
13.4.3 Merck Sharp and Dohme Fibromyalgia Drugs Introduction
13.4.4 Merck Sharp and Dohme Revenue in Fibromyalgia Drugs Business (2015-2020)
13.4.5 Merck Sharp and Dohme Recent Development
13.5 Daiichi Sankyo
13.5.1 Daiichi Sankyo Company Details
13.5.2 Daiichi Sankyo Business Overview
13.5.3 Daiichi Sankyo Fibromyalgia Drugs Introduction
13.5.4 Daiichi Sankyo Revenue in Fibromyalgia Drugs Business (2015-2020)
13.5.5 Daiichi Sankyo Recent Development
13.6 Innovative Med Concepts
13.6.1 Innovative Med Concepts Company Details
13.6.2 Innovative Med Concepts Business Overview
13.6.3 Innovative Med Concepts Fibromyalgia Drugs Introduction
13.6.4 Innovative Med Concepts Revenue in Fibromyalgia Drugs Business (2015-2020)
13.6.5 Innovative Med Concepts Recent Development
13.7 Meda
13.7.1 Meda Company Details
13.7.2 Meda Business Overview
13.7.3 Meda Fibromyalgia Drugs Introduction
13.7.4 Meda Revenue in Fibromyalgia Drugs Business (2015-2020)
13.7.5 Meda Recent Development
13.8 Meiji Seika
13.8.1 Meiji Seika Company Details
13.8.2 Meiji Seika Business Overview
13.8.3 Meiji Seika Fibromyalgia Drugs Introduction
13.8.4 Meiji Seika Revenue in Fibromyalgia Drugs Business (2015-2020)
13.8.5 Meiji Seika Recent Development
13.9 Switch Biotech
13.9.1 Switch Biotech Company Details
13.9.2 Switch Biotech Business Overview
13.9.3 Switch Biotech Fibromyalgia Drugs Introduction
13.9.4 Switch Biotech Revenue in Fibromyalgia Drugs Business (2015-2020)
13.9.5 Switch Biotech Recent Development
13.10 Theravance
13.10.1 Theravance Company Details
13.10.2 Theravance Business Overview
13.10.3 Theravance Fibromyalgia Drugs Introduction
13.10.4 Theravance Revenue in Fibromyalgia Drugs Business (2015-2020)
13.10.5 Theravance Recent Development
13.11 Zynerba Pharmaceuticals
10.11.1 Zynerba Pharmaceuticals Company Details
10.11.2 Zynerba Pharmaceuticals Business Overview
10.11.3 Zynerba Pharmaceuticals Fibromyalgia Drugs Introduction
10.11.4 Zynerba Pharmaceuticals Revenue in Fibromyalgia Drugs Business (2015-2020)
10.11.5 Zynerba Pharmaceuticals Recent Development
13.12 Tonix Pharmaceuticals Holding Corp. (TNXP)
10.12.1 Tonix Pharmaceuticals Holding Corp. (TNXP) Company Details
10.12.2 Tonix Pharmaceuticals Holding Corp. (TNXP) Business Overview
10.12.3 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Drugs Introduction
10.12.4 Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue in Fibromyalgia Drugs Business (2015-2020)
10.12.5 Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Fibromyalgia Drugs Revenue
1.4 Market by Type
1.4.1 Global Fibromyalgia Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Serotonin Norepinephrine Reuptake Inhibitors
1.4.3 GABA Analogs
1.4.4 Other
1.5 Market by Application
1.5.1 Global Fibromyalgia Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Fibromyalgia Drugs Market Perspective (2015-2026)
2.2 Global Fibromyalgia Drugs Growth Trends by Regions
2.2.1 Fibromyalgia Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Fibromyalgia Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Fibromyalgia Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Fibromyalgia Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Fibromyalgia Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Fibromyalgia Drugs Players by Market Size
3.1.1 Global Top Fibromyalgia Drugs Players by Revenue (2015-2020)
3.1.2 Global Fibromyalgia Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Fibromyalgia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Fibromyalgia Drugs Market Concentration Ratio
3.2.1 Global Fibromyalgia Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Fibromyalgia Drugs Revenue in 2019
3.3 Fibromyalgia Drugs Key Players Head office and Area Served
3.4 Key Players Fibromyalgia Drugs Product Solution and Service
3.5 Date of Enter into Fibromyalgia Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Fibromyalgia Drugs Historic Market Size by Type (2015-2020)
4.2 Global Fibromyalgia Drugs Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Fibromyalgia Drugs Market Size by Application (2015-2020)
5.2 Global Fibromyalgia Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Fibromyalgia Drugs Market Size (2015-2020)
6.2 Fibromyalgia Drugs Key Players in North America (2019-2020)
6.3 North America Fibromyalgia Drugs Market Size by Type (2015-2020)
6.4 North America Fibromyalgia Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Fibromyalgia Drugs Market Size (2015-2020)
7.2 Fibromyalgia Drugs Key Players in Europe (2019-2020)
7.3 Europe Fibromyalgia Drugs Market Size by Type (2015-2020)
7.4 Europe Fibromyalgia Drugs Market Size by Application (2015-2020)
8 China
8.1 China Fibromyalgia Drugs Market Size (2015-2020)
8.2 Fibromyalgia Drugs Key Players in China (2019-2020)
8.3 China Fibromyalgia Drugs Market Size by Type (2015-2020)
8.4 China Fibromyalgia Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Fibromyalgia Drugs Market Size (2015-2020)
9.2 Fibromyalgia Drugs Key Players in Japan (2019-2020)
9.3 Japan Fibromyalgia Drugs Market Size by Type (2015-2020)
9.4 Japan Fibromyalgia Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Fibromyalgia Drugs Market Size (2015-2020)
10.2 Fibromyalgia Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Fibromyalgia Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Fibromyalgia Drugs Market Size by Application (2015-2020)
11 India
11.1 India Fibromyalgia Drugs Market Size (2015-2020)
11.2 Fibromyalgia Drugs Key Players in India (2019-2020)
11.3 India Fibromyalgia Drugs Market Size by Type (2015-2020)
11.4 India Fibromyalgia Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Fibromyalgia Drugs Market Size (2015-2020)
12.2 Fibromyalgia Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Fibromyalgia Drugs Market Size by Type (2015-2020)
12.4 Central & South America Fibromyalgia Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Fibromyalgia Drugs Introduction
13.1.4 Pfizer Revenue in Fibromyalgia Drugs Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Eli Lilly
13.2.1 Eli Lilly Company Details
13.2.2 Eli Lilly Business Overview
13.2.3 Eli Lilly Fibromyalgia Drugs Introduction
13.2.4 Eli Lilly Revenue in Fibromyalgia Drugs Business (2015-2020)
13.2.5 Eli Lilly Recent Development
13.3 Actavis
13.3.1 Actavis Company Details
13.3.2 Actavis Business Overview
13.3.3 Actavis Fibromyalgia Drugs Introduction
13.3.4 Actavis Revenue in Fibromyalgia Drugs Business (2015-2020)
13.3.5 Actavis Recent Development
13.4 Merck Sharp and Dohme
13.4.1 Merck Sharp and Dohme Company Details
13.4.2 Merck Sharp and Dohme Business Overview
13.4.3 Merck Sharp and Dohme Fibromyalgia Drugs Introduction
13.4.4 Merck Sharp and Dohme Revenue in Fibromyalgia Drugs Business (2015-2020)
13.4.5 Merck Sharp and Dohme Recent Development
13.5 Daiichi Sankyo
13.5.1 Daiichi Sankyo Company Details
13.5.2 Daiichi Sankyo Business Overview
13.5.3 Daiichi Sankyo Fibromyalgia Drugs Introduction
13.5.4 Daiichi Sankyo Revenue in Fibromyalgia Drugs Business (2015-2020)
13.5.5 Daiichi Sankyo Recent Development
13.6 Innovative Med Concepts
13.6.1 Innovative Med Concepts Company Details
13.6.2 Innovative Med Concepts Business Overview
13.6.3 Innovative Med Concepts Fibromyalgia Drugs Introduction
13.6.4 Innovative Med Concepts Revenue in Fibromyalgia Drugs Business (2015-2020)
13.6.5 Innovative Med Concepts Recent Development
13.7 Meda
13.7.1 Meda Company Details
13.7.2 Meda Business Overview
13.7.3 Meda Fibromyalgia Drugs Introduction
13.7.4 Meda Revenue in Fibromyalgia Drugs Business (2015-2020)
13.7.5 Meda Recent Development
13.8 Meiji Seika
13.8.1 Meiji Seika Company Details
13.8.2 Meiji Seika Business Overview
13.8.3 Meiji Seika Fibromyalgia Drugs Introduction
13.8.4 Meiji Seika Revenue in Fibromyalgia Drugs Business (2015-2020)
13.8.5 Meiji Seika Recent Development
13.9 Switch Biotech
13.9.1 Switch Biotech Company Details
13.9.2 Switch Biotech Business Overview
13.9.3 Switch Biotech Fibromyalgia Drugs Introduction
13.9.4 Switch Biotech Revenue in Fibromyalgia Drugs Business (2015-2020)
13.9.5 Switch Biotech Recent Development
13.10 Theravance
13.10.1 Theravance Company Details
13.10.2 Theravance Business Overview
13.10.3 Theravance Fibromyalgia Drugs Introduction
13.10.4 Theravance Revenue in Fibromyalgia Drugs Business (2015-2020)
13.10.5 Theravance Recent Development
13.11 Zynerba Pharmaceuticals
10.11.1 Zynerba Pharmaceuticals Company Details
10.11.2 Zynerba Pharmaceuticals Business Overview
10.11.3 Zynerba Pharmaceuticals Fibromyalgia Drugs Introduction
10.11.4 Zynerba Pharmaceuticals Revenue in Fibromyalgia Drugs Business (2015-2020)
10.11.5 Zynerba Pharmaceuticals Recent Development
13.12 Tonix Pharmaceuticals Holding Corp. (TNXP)
10.12.1 Tonix Pharmaceuticals Holding Corp. (TNXP) Company Details
10.12.2 Tonix Pharmaceuticals Holding Corp. (TNXP) Business Overview
10.12.3 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Drugs Introduction
10.12.4 Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue in Fibromyalgia Drugs Business (2015-2020)
10.12.5 Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
